Unraveling the Complexity of Cancer-Related Cognitive Impairment in Breast CancerUnraveling the Complexity of Cancer-Related Cognitive Impairment in Breast Cancer
Cancer-related cognitive impairment (CRCI) is an important clinical problem that affects many patients with cancer and includes difficulties in memory, attention, processing speed, and executive function. Studies including patient-reported outcomes (PROs) suggest that 50% to 75% of patients receiving chemotherapy experience CRCI. These problems negatively affect daily functioning and can persist for many years. Given that CRCI exists in the short and long term, better understanding of the effect of disease and various treatment combinations on CRCI and whether there are differential effects in the magnitude of CRCI by treatment regimen and the contributions of host factors is needed.
Sleeve gastrectomy may produce greater and more durable weight loss than semaglutide in patients with obesitySleeve gastrectomy may produce greater and more durable weight loss than semaglutide in patients with obesity
1. Sleeve gastrectomy produces substantially greater and more durable weight loss than semaglutide over 12 months in patients with obesity. 2. Semaglutide is effective during treatment, but discontinuation frequently leads to clinically significant weight regain, highlighting the need for long-term treatment strategies. Evidence Rating Level: 2 (Good) In this prospective, non-randomized study, sleeve gastrectomy (SG) Read More
GLP-1 Warning Over Link to Fatal Events; DOJ Sues Med School; Genes and LongevityGLP-1 Warning Over Link to Fatal Events; DOJ Sues Med School; Genes and Longevity
(MedPage Today) — Note that some links may require registration or subscription. The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include… (MedPage Today) — Note that some links may require registration or subscription. The United Kingdom’s Medicines and Healthcare Products Regulatory Read More
AI-assisted mammograms cut risk of developing aggressive breast cancerAI-assisted mammograms cut risk of developing aggressive breast cancer
Interval cancers are aggressive tumours that grow during the interval after someone has been screened for cancer and before they are screened again, and AI seems to be able to identify them at an early stage
AI-supported mammography screening results in fewer aggressive and advanced breast cancersAI-supported mammography screening results in fewer aggressive and advanced breast cancers
Artificial intelligence (AI)-supported mammography identifies more cancers during screening and reduces the rate of breast cancer diagnosis by 12% in the years following, finds the first randomized controlled trial of its kind. The trial involved over 100,000 Swedish women, and its results are published in The Lancet.
AI use in breast cancer screening cuts rate of later diagnosis by 12%, study findsAI use in breast cancer screening cuts rate of later diagnosis by 12%, study finds
Swedish study of 100,000 women found higher rate of early detection, suggesting potential to support radiologistsThe use of artificial intelligence in breast cancer screening reduces the rate of a cancer diagnosis by 12% in subsequent years and leads to a higher rate of early detection, according to the first trial of its kind.Researchers said the study was the largest to date looking at AI use in cancer screening. It involved 100,000 women in Sweden who were part of mammography screening and were randomly assigned to either AI-supported screening or to a standard reading by two radiologists between April 2021 and December 2022. Continue reading…
Amputation Risk in Diabetes Drops With GLP-1 Drugs, Study SuggestsAmputation Risk in Diabetes Drops With GLP-1 Drugs, Study Suggests
(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed. Among 17,288 patients, new… (MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major Read More
There Are Many Types of Obesity, Says This GLP-1 ExpertThere Are Many Types of Obesity, Says This GLP-1 Expert
A renowned physician-scientist says treatment is not one-size-fits-all. A renowned physician-scientist says treatment is not one-size-fits-all.
GLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBSGLP-1 Drugs and Liver Complications; Tracking Endoscopists’ Eyes; Peppermint for IBS
(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes patients compared with other glucose-lowering therapies, a systematic… (MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) Read More
Blood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancerBlood biomarker points to increased risk of brain metastasis in patients with inflammatory breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer. The study uncovers a novel role for soluble E-cadherin (sEcad) in promoting tumor invasion while resisting cancer cell death and triggering brain inflammation via the CXCR2 signaling pathway.